This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Interferon beta-1a at 30 mcg administered IM once weekly is indicated for relapsing forms of MS. In addition, Glatiramer acetate at 20 mcg administered daily SQ injections is indicated for relapsing-remitting MS.
Showing the most recent 10 out of 426 publications